trastuzumab deruxtecan

Ukraine

Drugs containing this active substance

  • ENHERTU

    The drug is prescribed to adults for the treatment of HER2-positive breast cancer (including cases with low HER2 expression), advanced non-small cell lung cancer with HER2 mutation, as well as HER2-positive gastric or gastroesophageal junction adenocarcinoma.

    Form: powder for concentrate for infusion solution

    Active substance Dosage
    trastuzumab deruxtecan 100 mg

    ATC: L01FD04

    Manufacturer: Baxter Oncology GmbH (manufacturing, quality control testing at batch release (except cell growth inhibition))